Association between Serum Ferritin and Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Table 1
Baseline clinical characteristics between patients with CIN and those without CIN.
Variables
CIN
Non-CIN
value
Age (years)
<0.001
Male, (%)
64 (66.7)
335 (74.1)
0.136
BMI (kg/m2)
0.279
Systolic BP (mmHg)
0.955
Type of ACS, (%)
<0.001
STEMI
19 (19.8)
32 (7.1)
NSTEMI
36 (37.5)
121 (26.8)
UA
41 (42.7)
299 (66.2)
Smoking, (%)
35 (36.5)
198 (43.8)
0.186
Hypertension, (%)
71 (74.0)
271 (60.0)
0.01
Diabetes mellitus, (%)
57 (59.4)
117 (25.9)
<0.001
LVEF (%)
<0.001
Number of diseased vessels, (%)
0.034
1
23 (24.0)
150 (33.2)
2
29 (30.2)
156 (34.5)
3
44 (45.8)
146 (32.3)
Contrast dose (mL)
0.133
Hydration, (%)
62 (64.6)
302 (66.8)
0.674
Medication, (%)
Aspirin
89 (92.7)
420 (92.9)
0.942
β-Blocker
70 (72.9)
335 (74.1)
0.808
Statin
90 (93.8)
415 (91.8)
0.522
ACEI/ARB
69 (71.9)
333 (73.7)
0.717
CCB
24 (25.0)
126 (27.9)
0.566
Data are mean ± standard deviation or number (%). BMI, body mass index; BP, blood pressure; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
